Brief: Acumen Pharmaceuticals, Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE Technology

Acumen Pharmaceuticals

06/11/2023 14:10

Nov 6 (Reuters) - Acumen Pharmaceuticals Inc  ABOS.O :
    * ACUMEN PHARMACEUTICALS, INC. AND HALOZYME ENTER GLOBAL
COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS
FORMULATION OF ACU193 WITH ENHANZE® TECHNOLOGY
    * ACUMEN PHARMACEUTICALS : ACUMEN INTENDS TO EXPLORE USING
ENHANZE
WITH ACU193 AND PLANS TO INITIATE PHASE 1 DEVELOPMENT IN HUMAN
SUBJECTS IN MID-2024
    * ACUMEN PHARMACEUTICALS-  UNDER TERMS OF DEAL, IN RETURN
FOR
UPFRONT PAYMENT TO HALOZYME, ACUMEN WILL RECEIVE NON-EXCLUSIVE
RIGHTS TO ENHANZE

Source text for Eikon:  ID:nGNXqCpWx 
Further company coverage:  ABOS.O 

 ((Reuters.Briefs@thomsonreuters.com;))